Neoadjuvant Chemotherapy for Locally Advanced Squamous Carcinoma of Oral Cavity: a Pilot Study
To evaluate the effect of adding neoadjuvant chemotherapy to surgery and radiation therapy for locally advanced resectable oral cavity squamous cell carcinoma, 24 patients with T3 or T4a oral cavity squamous cell carcinoma were randomly assigned to surgery alone or Docetaxel, Cisplatin, and 5-FU (T...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Tehran University of Medical Sciences
2015-06-01
|
Series: | Acta Medica Iranica |
Subjects: | |
Online Access: | https://acta.tums.ac.ir/index.php/acta/article/view/4872 |
id |
doaj-0a412fec45744eb9a3b2d0b86ec71467 |
---|---|
record_format |
Article |
spelling |
doaj-0a412fec45744eb9a3b2d0b86ec714672020-11-25T03:35:01ZengTehran University of Medical SciencesActa Medica Iranica0044-60251735-96942015-06-015364825Neoadjuvant Chemotherapy for Locally Advanced Squamous Carcinoma of Oral Cavity: a Pilot StudySanambar Sadighi0Amanolah Keyhani1Iraj Harirchi2Ata Garajei3Mahdi Aghili4Ali Kazemian5Maziar Motiee Langroudi6Kazem Zendehdel7Nariman Nikparto8Cancer Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran.Department of Head and Neck Surgical Oncology and Reconstructive Surgery, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran.Department of Head and Neck Surgical Oncology and Reconstructive Surgery, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran.Department of Head and Neck Surgical Oncology and Reconstructive Surgery, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran.Radiotherapy Oncology Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran.Radiotherapy Oncology Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran.Department of Ear, Nose and Trout, Valiasr Hospital, Cancer Research Center, Tehran University of Medical Sciences, Tehran, Iran.Cancer Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran.Cancer Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran. To evaluate the effect of adding neoadjuvant chemotherapy to surgery and radiation therapy for locally advanced resectable oral cavity squamous cell carcinoma, 24 patients with T3 or T4a oral cavity squamous cell carcinoma were randomly assigned to surgery alone or Docetaxel, Cisplatin, and 5-FU (TPF) induction chemotherapy followed by surgery. All patients were planned to receive chemoradiotherapy after surgery. The primary end-points were organ preservation and progression-free-survival. SPSS version 17 was used for data analysis. Median follow-up was 16 months. The median age of the patients was 62 years old (23-75 years). Man/woman ratio was 1.13. The primary site of the tumor was the tongue in most patients (48%). No significant difference was observed between pathologic characteristics of the two groups. Chemotherapy group showed 16% complete pathologic response to TPF. No significant difference in organ preservation surgery or overall survival was detected. However, the patients in the chemotherapy group had longer progression-free-survival (P=0.014). Surgery followed by chemoradiotherapy with or without TPF induction results in similar survival time. However, progression-free-survival improves with the TPF induction chemotherapy. Studies with more patents and new strategies are recommended to evaluate organ preservation improvement and long-term outcomes. https://acta.tums.ac.ir/index.php/acta/article/view/4872Oral cavitySquamous cell carcinomaRandomized clinical trialInduction chemotherapy |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Sanambar Sadighi Amanolah Keyhani Iraj Harirchi Ata Garajei Mahdi Aghili Ali Kazemian Maziar Motiee Langroudi Kazem Zendehdel Nariman Nikparto |
spellingShingle |
Sanambar Sadighi Amanolah Keyhani Iraj Harirchi Ata Garajei Mahdi Aghili Ali Kazemian Maziar Motiee Langroudi Kazem Zendehdel Nariman Nikparto Neoadjuvant Chemotherapy for Locally Advanced Squamous Carcinoma of Oral Cavity: a Pilot Study Acta Medica Iranica Oral cavity Squamous cell carcinoma Randomized clinical trial Induction chemotherapy |
author_facet |
Sanambar Sadighi Amanolah Keyhani Iraj Harirchi Ata Garajei Mahdi Aghili Ali Kazemian Maziar Motiee Langroudi Kazem Zendehdel Nariman Nikparto |
author_sort |
Sanambar Sadighi |
title |
Neoadjuvant Chemotherapy for Locally Advanced Squamous Carcinoma of Oral Cavity: a Pilot Study |
title_short |
Neoadjuvant Chemotherapy for Locally Advanced Squamous Carcinoma of Oral Cavity: a Pilot Study |
title_full |
Neoadjuvant Chemotherapy for Locally Advanced Squamous Carcinoma of Oral Cavity: a Pilot Study |
title_fullStr |
Neoadjuvant Chemotherapy for Locally Advanced Squamous Carcinoma of Oral Cavity: a Pilot Study |
title_full_unstemmed |
Neoadjuvant Chemotherapy for Locally Advanced Squamous Carcinoma of Oral Cavity: a Pilot Study |
title_sort |
neoadjuvant chemotherapy for locally advanced squamous carcinoma of oral cavity: a pilot study |
publisher |
Tehran University of Medical Sciences |
series |
Acta Medica Iranica |
issn |
0044-6025 1735-9694 |
publishDate |
2015-06-01 |
description |
To evaluate the effect of adding neoadjuvant chemotherapy to surgery and radiation therapy for locally advanced resectable oral cavity squamous cell carcinoma, 24 patients with T3 or T4a oral cavity squamous cell carcinoma were randomly assigned to surgery alone or Docetaxel, Cisplatin, and 5-FU (TPF) induction chemotherapy followed by surgery. All patients were planned to receive chemoradiotherapy after surgery. The primary end-points were organ preservation and progression-free-survival. SPSS version 17 was used for data analysis. Median follow-up was 16 months. The median age of the patients was 62 years old (23-75 years). Man/woman ratio was 1.13. The primary site of the tumor was the tongue in most patients (48%). No significant difference was observed between pathologic characteristics of the two groups. Chemotherapy group showed 16% complete pathologic response to TPF. No significant difference in organ preservation surgery or overall survival was detected. However, the patients in the chemotherapy group had longer progression-free-survival (P=0.014). Surgery followed by chemoradiotherapy with or without TPF induction results in similar survival time. However, progression-free-survival improves with the TPF induction chemotherapy. Studies with more patents and new strategies are recommended to evaluate organ preservation improvement and long-term outcomes.
|
topic |
Oral cavity Squamous cell carcinoma Randomized clinical trial Induction chemotherapy |
url |
https://acta.tums.ac.ir/index.php/acta/article/view/4872 |
work_keys_str_mv |
AT sanambarsadighi neoadjuvantchemotherapyforlocallyadvancedsquamouscarcinomaoforalcavityapilotstudy AT amanolahkeyhani neoadjuvantchemotherapyforlocallyadvancedsquamouscarcinomaoforalcavityapilotstudy AT irajharirchi neoadjuvantchemotherapyforlocallyadvancedsquamouscarcinomaoforalcavityapilotstudy AT atagarajei neoadjuvantchemotherapyforlocallyadvancedsquamouscarcinomaoforalcavityapilotstudy AT mahdiaghili neoadjuvantchemotherapyforlocallyadvancedsquamouscarcinomaoforalcavityapilotstudy AT alikazemian neoadjuvantchemotherapyforlocallyadvancedsquamouscarcinomaoforalcavityapilotstudy AT maziarmotieelangroudi neoadjuvantchemotherapyforlocallyadvancedsquamouscarcinomaoforalcavityapilotstudy AT kazemzendehdel neoadjuvantchemotherapyforlocallyadvancedsquamouscarcinomaoforalcavityapilotstudy AT narimannikparto neoadjuvantchemotherapyforlocallyadvancedsquamouscarcinomaoforalcavityapilotstudy |
_version_ |
1724556065596506112 |